Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis

Pharmacotherapy

Volumn 36, Issue 1, 2016, Pages 13-18

  Autry, Elizabeth B ^a,b   Rybak, Jeffrey M ^a   Leung, Noelle R ^a,b   Gardner, Brian M ^a,b   Burgess, Donna R ^a,b   Anstead, Michael I ^b   Kuhn, Robert J ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

ceftaroline; cystic fibrosis; methicillin resistant Staphylococcus aureus; pharmacodynamics; pharmacokinetics

Indexed keywords

CEFTAROLINE FOSAMIL; ANTIINFECTIVE AGENT; CEFTAROLINE; CEPHALOSPORIN DERIVATIVE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; LIMIT OF DETECTION; MALE; MASS SPECTROMETRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OBSERVATIONAL STUDY; OPEN STUDY; PHLEBITIS; PROSPECTIVE STUDY; PRURITUS; RASH; STEADY STATE; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84960896340     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1681     Document Type: Article

References (10)

1. Forest Laboratories, Inc. Teflaro (ceftaroline) package insert. St. Louis, MO; 2010.
2. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, et al., Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010; 303: 2386-92.
3. Udy AA, Roberts JA, Lipman J,. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol 2011; 7: 539-43.
4. Xu A,. Analytical procedure for the quantification of ceftaroline, ceftaroline fosamil, and ceftaroline open ring metabolite in human Na2EDTA/NaF plasma by LC/MS/MS. North Wales, PA: Keystone Bioanalytical, Inc., 2013.
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-third informational supplement. Document M100-S23. Wayne, PA: CSI, 2013.
6. Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, et al., Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II cephalosporins and penicillins. Pediatr Pulmonol 2013; 48: 107-22.
7. Huls CE, Prince RA, Seilherimer DK, Bosso JA,. Pharmacokinetics of cefepime in cystic fibrosis patients. Antimicrob Agents Chemother 1993; 37: 1414-6.
8. Drusano GL,. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity. J Antimicrob Chemother 2010; 65: iv33-9.
9. MacGowan AP, Noel AR, Tomaselli S, Bowker KE,. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 2013; 57: 2451-6.
10. Zhanel GG, Rossnagel E, Nichol K, Cox L, Karlowsky JA, et al., Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus, and vancomycin-resistant S. aureus using an in vitro model. J Antimicrob Chemother 2011; 66: 1301-5.